A major clinical trial evaluating Novartis’ experimental cardiovascular treatment, pelacarsen, has fallen short of significantly improving patient outcomes, despite successfully reducing levels of a harmful type of cholesterol known as lipoprotein(a), or Lp(a). Developed in partnership with Ionis Pharmaceuticals, the drug’s inability to lower cardiovascular events in a late-stage study has sent ripples through the […]